Genotype-Dependent Tumor Regression in Marek’s Disease Mediated at the Level of Tumor Immunity

Marek’s disease (MD) of chickens is a unique natural model of Hodgkin’s and Non Hodgkin’s lymphomas in which the neoplastically-transformed cells over-express CD30 (CD30hi) antigen. All chicken genotypes can be infected with MD virus and develop microscopic lymphomas. From 21 days post infection (dpi) microscopic lymphomas regress in resistant chickens but, in contrast, they progress to gross lymphomas in susceptible chickens. Here we test our hypothesis that in resistant chickens at 21 dpi the tissue microenvironment is pro T-helper (Th)-1 and compatible with cytotoxic T lymphocyte (CTL) immunity but in susceptible lines it is pro Th-2 or pro T-regulatory (T-reg) and antagonistic to CTL immunity. We used the B2, non-MHC-associated, MD resistance/susceptibility system (line [L]61/line [L]72) and quantified the levels of key mRNAs that can be used to define Th-1 (IL-2, IL-12, IL-18, IFNγ), Th-2 (IL-4, IL-10) and T-reg (TGFβ, GPR-83, CTLA-4, SMAD-7) lymphocyte phenotypes. We measured gene expression in both whole tissues (represents tissue microenvironment and tumor microenvironment) and in the lymphoma lesions (tumor microenvironment) themselves. Gene ontology-based modeling of our results shows that the dominant phenotype in whole tissue as well as in microscopic lymphoma lesions, is pro T-reg in both L61 and L72 but a minor pro Th-1 and anti Th-2 tissue microenvironment exists in L61 whereas there is an anti Th-1 and pro Th-2 tissue microenvironment in L72. The tumor microenvironment per se is pro T-reg, anti Th-1 and pro Th-2 in both L61 and L72. Together our data suggests that the neoplastic transformation is essentially the same in both L61 and L72 and that resistance/susceptibility is mediated at the level of tumor immunity in the tissues.

[1]  S. Burgess,et al.  Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Togashi,et al.  Critical role of the Th1/Tc1 circuit for the generation of tumor‐specific CTL during tumor eradication in vivo by Th1‐cell therapy , 2003, Cancer science.

[3]  S. Sharif,et al.  Marek's disease virus induces Th-2 activity during cytolytic infection. , 2008, Viral immunology.

[4]  J. Buer,et al.  G Protein-Coupled Receptor 83 Overexpression in Naive CD4+CD25− T Cells Leads to the Induction of Foxp3+ Regulatory T Cells In Vivo1 , 2006, The Journal of Immunology.

[5]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[6]  N. Restifo,et al.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. , 2005, Journal of immunotherapy.

[7]  S. Sharif,et al.  Cytokine gene expression patterns associated with immunization against Marek's disease in chickens. , 2007, Vaccine.

[8]  B. Sander,et al.  CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma , 2007, Clinical Cancer Research.

[9]  P. Kaiser,et al.  Infectious bursal disease virus: strains that differ in virulence differentially modulate the innate immune response to infection in the chicken bursa. , 2006, Viral immunology.

[10]  K. Miyazono TGF-beta signaling by Smad proteins. , 2000, Cytokine & growth factor reviews.

[11]  K. Schat,et al.  Expression of cytokine genes in Marek's disease virus‐infected chickens and chicken embryo fibroblast cultures , 2000, Immunology.

[12]  E. El-Omar,et al.  Genetic aspects of inflammation and cancer. , 2008, The Biochemical journal.

[13]  M. Neurath,et al.  Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25− T Cells1 , 2007, The Journal of Immunology.

[14]  T. Mak,et al.  The role of cytokines in classical Hodgkin lymphoma. , 2002, Blood.

[15]  K. Schat,et al.  Inhibitory Effects of Nitric Oxide and Gamma Interferon on In Vitro and In Vivo Replication of Marek's Disease Virus , 2000, Journal of Virology.

[16]  B. Leung,et al.  CD4+CD25+ REGULATORY T CELLS IN HEALTH AND DISEASE , 2006, Clinical and experimental pharmacology & physiology.

[17]  P. Kaiser,et al.  Cytokine expression in chicken peripheral blood mononuclear cells after in vitro exposure to Salmonella enterica serovar Enteritidis. , 2006, Poultry science.

[18]  Marylène Lejeune,et al.  Tumor-Infiltrated Immune Response Correlates with Alterations in the Apoptotic and Cell Cycle Pathways in Hodgkin and Reed-Sternberg Cells , 2008, Clinical Cancer Research.

[19]  A. Rudensky,et al.  G Protein-Coupled Receptor 83 Is Dispensable for the Development and Function of Regulatory T Cells , 2007, Molecular and Cellular Biology.

[20]  A. O’Garra,et al.  The molecular basis of T helper 1 and T helper 2 cell differentiation. , 2000, Trends in cell biology.

[21]  F. McCarthy,et al.  GOing from functional genomics to biological significance , 2007, Cytogenetic and Genome Research.

[22]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Okamoto,et al.  NF-kappa B signaling and carcinogenesis. , 2007, Current pharmaceutical design.

[24]  K. Miyazono TGF-β signaling by Smad proteins , 2000 .

[25]  S. Burgess,et al.  Resistance to Marek's Disease Herpesvirus-induced Lymphoma is Multiphasic and Dependent on Host Genotype , 2001, Veterinary pathology.

[26]  J. Marx Cancer research. Inflammation and cancer: the link grows stronger. , 2004, Science.

[27]  Jean Marx,et al.  Inflammation and Cancer: The Link Grows Stronger , 2004, Science.

[28]  S. Burgess,et al.  The neoplastically transformed (CD30hi) Marek’s disease lymphoma cell phenotype most closely resembles T-regulatory cells , 2008, Cancer Immunology, Immunotherapy.

[29]  H. Oberg,et al.  Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. , 2006, Critical reviews in immunology.

[30]  P. Quéré,et al.  Abundance of IFN-α and IFN-γ mRNA in blood of resistant and susceptible chickens infected with Marek’s disease virus (MDV) or vaccinated with turkey herpesvirus; and MDV inhibition of subsequent induction of IFN gene transcription , 2004, Archives of Virology.

[31]  A. Rudensky,et al.  TGFbeta signalling in control of T-cell-mediated self-reactivity. , 2007, Nature reviews. Immunology.

[32]  A. Sánchez-Aguilera,et al.  Lymphoma microenvironment: culprit or innocent? , 2008, Leukemia.

[33]  I. Ernberg,et al.  Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. , 2008, The American journal of pathology.

[34]  John R. Young,et al.  Cloning and Characterization of Chicken IL-10 and Its Role in the Immune Response to Eimeria maxima1 , 2004, The Journal of Immunology.

[35]  H. Heslop,et al.  Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor , 2008, Journal of immunotherapy.

[36]  P. Kaiser,et al.  Differential Cytokine Responses following Marek's Disease Virus Infection of Chickens Differing in Resistance to Marek's Disease , 2003, Journal of Virology.

[37]  A. Abdelrazeq Spontaneous regression of colorectal cancer: a review of cases from 1900 to 2005 , 2007, International Journal of Colorectal Disease.

[38]  V. Imbert,et al.  Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. , 2006, Cellular signalling.

[39]  K. Mills,et al.  Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[40]  T. Okamoto,et al.  NF-κB Signaling and Carcinogenesis , 2007 .

[41]  Shane C. Burgess,et al.  Identification of the Neoplastically Transformed Cells in Marek's Disease Herpesvirus-Induced Lymphomas: Recognition by the Monoclonal Antibody AV37 , 2002, Journal of Virology.

[42]  Shane C Burgess,et al.  Modeling the proteome of a Marek's disease transformed cell line: a natural animal model for CD30 overexpressing lymphomas , 2007, Proteomics.

[43]  V. Schirrmacher,et al.  Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo. , 1999, International journal of oncology.

[44]  H. Kung,et al.  Characterization of the Chromosomal Binding Sites andDimerization Partners of the Viral Oncoprotein Meq in Marek'sDisease Virus-Transformed TCells , 2003, Journal of Virology.

[45]  M. Probst-Kepper,et al.  Signatures of human regulatory T cells: an encounter with old friends and new players , 2006, Genome Biology.

[46]  Zheng Xing,et al.  Specific and nonspecific immune responses to Marek's disease virus. , 2000, Developmental and comparative immunology.

[47]  O. Cummings,et al.  Differential Expression of Smad7 Transcripts Identifies the CD4+CD45RChigh Regulatory T Cells That Mediate Type V Collagen-Induced Tolerance to Lung Allografts 1 , 2003, The Journal of Immunology.

[48]  Toshiki Watanabe,et al.  CD30: expression and function in health and disease. , 1998, Seminars in immunology.